# Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

> **NCT06838832** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Non-hodgkin Lymphoma,B Cell

## Interventions

- **BIOLOGICAL:** Allogenic CD19-CAR-γδT cell
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06838832
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-27
- **Primary completion:** 2027-03-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06838832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06838832, "Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06838832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*